Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Beavers, Craig J.; Rodgers, Jo E.; Bagnola, Aaron; Beckie, Theresa M.; Campia, Umberto; Palo, Katherine E. Di; Okwuosa, Tochi M.; Przespolewski, Eugene; Dent, Susan

doi:10.1161/cir.0000000000001056

Cited by 48 publications

(41 citation statements)

References 139 publications

(374 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A statement about Cardio-Oncology drug interactions has been published. 18 It is possible that the results of this study were affected by drug interactions, however, they have not been investigated in detail.…”

Section: Discussionmentioning

confidence: 95%

Prognostic Factors for Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients Treated with Current Anthracycline Regimens

Egashira

Sueta

Tomiguchi

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Anthracycline therapies cause myocardial damage and the onset of heart failure, depending on their doses. We investigated prognostic factors for cancer therapeutics-related cardiac dysfunction (CTRCD) in patients receiving modern anthracycline therapies. Methods: We retrospective investigated 625 consecutive patients who were diagnosed with breast cancer and received anthracycline therapy at Kumamoto University Hospital between January 2007 and December 2018. We excluded 153 patients because of missing data, and the remaining 472 patients were enrolled in this study. The primary endpoint was the onset of CTRCD. The exact observation end date was December 31, 2020. Results: Of 472 breast cancer patients with complete data treated with anthracycline, 8 were diagnosed with CTRCD. Multivariate regression analyses revealed that the anthracycline cumulative dose, concomitant use of molecular targeted drugs and a prechemotherapy left ventricular ejection fraction < 50% were independent and significant predictors of the onset of CTRCD. Conclusions: Even in the modern era, the anthracycline cumulative dose is an independent risk factor for the onset of CTRCD.

show abstract

Section: Discussionmentioning

confidence: 95%

Prognostic Factors for Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients Treated with Current Anthracycline Regimens

Egashira

Sueta

Tomiguchi

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Many cancer regimens have prothrombotic properties. Some antineoplastic agents have been represented a signi cant source of added VTE risk and morbidity and mortality, such as tamoxifen and bevacizumab [45]. The management of cancer in older people is becoming a common problem owing to an aging population.…”

Section: Discussionmentioning

confidence: 99%

Comorbidities in patients with uterine adenosarcoma. A single-center case series of 12 patients

Jiang

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Uterine adenosarcoma is a rare low-grade tumor that commonly affects elderly women and is associated with a generally good, although sometimes poor, prognosis. This study investigates the effect of comorbidities in old patients with uterine adenosarcoma. Methods: A review of patients who had been diagnosed with uterine adenosarcoma at our institution between 2010 and 2020 was conducted. All patients underwent a specialist pathological reviewand were re-staged according to the International Federation of Gynecology and Obstetrics 2009 criteria. Patient demographics, staging, histologic features, primary and adjuvant therapy, disease recurrence, and survival time were collected. Results: Twelve patients with confirmed uterine adenosarcomas were identified. Their mean age at diagnosis was 58.3 years (range, 31–83 years). Eight patients had pre-existing chronic diseases at the time of diagnosis. All 12 patients underwent surgical therapy. Of these, 10 (83.3%) were stage I, 1 (8.3%) was stage II, and 1 (8.3%) was stage III. Postoperative adjuvant therapies included chemotherapy (n = 1), radiation (n = 1), or no further therapy (n = 10). The mean follow-up duration was 39.2 months (range, 7–104 months). The recurrence and mortality rates were 16.7% (2/12) and 41.7% (5/12), respectively. Five recurrence-free patients died of comorbidities. The mean postoperative survival of these 5 patients was 22.6 months. The remaining seven patients were free of recurrence at the time of this report. Conclusions: Comorbidities with age is a significant factor leading to poor prognosis in uterine adenosarcomas. Greater attention should be paid to elderly patients with comorbidities. Targeted interventions, including multi-professional management, tailored assessment, and follow-up, may contribute to improved well-being.

show abstract

“…The increasing emphasis in recent years on evaluating and treating heart disease in cancer patients has been driven in large part by the known cardiotoxicity of many chemotherapeutic agents as well as pre-existing cardiovascular disease in many cancer patients [ 37 , 38 ]. These factors have led to growth in the field of cardio-oncology [ 39 ].…”

Section: Introductionmentioning

confidence: 99%

Cardiac Remodeling in Cancer-Induced Cachexia: Functional, Structural, and Metabolic Contributors

Wiggs

Beaudry

Law

2022

Cells

View full text Add to dashboard Cite

Cancer cachexia is a syndrome of progressive weight loss and muscle wasting occurring in many advanced cancer patients. Cachexia significantly impairs quality of life and increases mortality. Cardiac atrophy and dysfunction have been observed in patients with cachexia, which may contribute to cachexia pathophysiology. However, relative to skeletal muscle, little research has been carried out to understand the mechanisms of cardiomyopathy in cachexia. Here, we review what is known clinically about the cardiac changes occurring in cachexia, followed by further discussion of underlying physiological and molecular mechanisms contributing to cachexia-induced cardiomyopathy. Impaired cardiac contractility and relaxation may be explained by a complex interplay of significant heart muscle atrophy and metabolic remodeling, including mitochondrial dysfunction. Because cardiac muscle has fundamental differences compared to skeletal muscle, understanding cardiac-specific effects of cachexia may bring light to unique therapeutic targets and ultimately improve clinical management for patients with cancer cachexia.

show abstract

Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Cited by 48 publications

References 139 publications

Prognostic Factors for Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients Treated with Current Anthracycline Regimens

Prognostic Factors for Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients Treated with Current Anthracycline Regimens

Comorbidities in patients with uterine adenosarcoma. A single-center case series of 12 patients

Cardiac Remodeling in Cancer-Induced Cachexia: Functional, Structural, and Metabolic Contributors

Contact Info

Product

Resources

About